AEST
1030 Welcome I DLBCL treatment – Current challenges & the evolving landscape
1110 Exploring EPKINLY’s study data and it’s clinical application
1150 EPKINLY: Practical insights for effective patient management
1230 Lunch Break
1330 Real world learnings & guidelines from UK & Case Study
1435 2 x Case Studies
1505 Q&A session
1530 Close
Indication: EPKINLY is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. EPKINLY is not indicated for the treatment of patients with primary central nervous system lymphoma.
This medicine has provisional approval in Australia for the treatment of adult patients with relapsed or refractory DLBCL after two or more lines of systemic therapy.
The decision to approve this indication has been made on the basis of overall response and duration of response from an uncontrolled, open label phase I/II study.
Continued approval of this indication depends on verifications and description of benefit in confirmatory trials.
Safety profile: The most common adverse drug reactions of any grade (≥ 20%) were: injection site reactions, cytokine release syndrome (CRS), neutropenia, pyrexia, nausea, diarrhoea.1
WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITY including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME.
Cytokine release syndrome (CRS) can occur in patients receiving EPKINLY.
Neurological toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), and serious and life-threatening reactions can occur in patients receiving EPKINLY.
Manage per section 4.2 Dose and method of administration, Dosage modifications and management of adverse reactions, in consultation with the patient’s physician.
Refer to Product Information.
PBS Information: Authority required (Telephone/online for induction, Streamlined for continuing phase).
For treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least 2 prior systemic therapies.
Refer to PBS Schedule for full authority information.
Please review full product information (PI) before prescribing.
Full PI is available from AbbVie Pty Ltd by calling 1800 043 460 or https://abbv.ie/au-epkin-pi
CRS: cytokine release syndrome DLBCL: diffuxe large B-cell lymphoma.
Reference: 1. Epkinly Product Information.
Adverse events should be reported to the Abbie office at (AU) 1800 252 224, [email protected] or to your local health authority.
AbbVie® is a registered trademark of AbbVie Inc.
EPKINLY® and its design are trademarks of AbbVie Biotechnology Ltd.
AbbVie Pty Ltd. ABN 48 156 384 262. 241 O’Riordan Street, Mascot NSW 2020. Medical Information phone: 1800 043 460.
AU-EDLBCL-250078. Date prepared: May 2025.
